Femasys Inc (FEMY)

Mar 27, 2025, 9:00 AM EDT - 25 days ago

Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

Mar 19, 2025, 9:20 AM EDT - 4 weeks ago

Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations

Mar 18, 2025, 9:00 AM EDT - 4 weeks ago

Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain

Mar 13, 2025, 8:30 AM EDT - 5 weeks ago

Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach

Feb 25, 2025, 9:20 AM EST - 7 weeks ago

Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials

Feb 11, 2025, 9:00 AM EST - 2 months ago

Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices

Jan 30, 2025, 8:30 AM EST - 2 months ago

Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control

Jan 16, 2025, 8:30 AM EST - 3 months ago

Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment

Nov 26, 2024, 8:30 AM EST - 5 months ago

Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment

Nov 12, 2024, 8:30 AM EST - 5 months ago

Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

Nov 1, 2024, 8:30 AM EDT - 6 months ago

Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control

Oct 10, 2024, 8:30 AM EDT - 6 months ago

Femasys to Exhibit at ASRM 2024 and Participate in the Congress' KEEPR Education Program

Oct 2, 2024, 8:30 AM EDT - 7 months ago

Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments

Sep 18, 2024, 8:30 AM EDT - 7 months ago

Femasys Announces Infertility Clinic Customers from Coast to Coast

Sep 11, 2024, 8:30 AM EDT - 7 months ago

Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market

Sep 9, 2024, 8:30 AM EDT - 8 months ago

Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check

Sep 5, 2024, 8:30 AM EDT - 8 months ago

Femasys to Exhibit at The Canadian Fertility and Andrology Society's 70th Annual Meeting

Sep 3, 2024, 8:30 AM EDT - 8 months ago

Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 29, 2024, 8:30 AM EDT - 8 months ago

Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution

Aug 27, 2024, 8:30 AM EDT - 8 months ago

Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters

Aug 8, 2024, 8:30 AM EDT - 9 months ago

Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update

Jun 27, 2024, 8:30 AM EDT - 10 months ago

Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam

May 17, 2024, 8:30 AM EDT - 1 year ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative

May 16, 2024, 8:30 AM EDT - 1 year ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Gender Policy Council

May 9, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update

May 7, 2024, 8:30 AM EDT - 1 year ago

Femasys Expands Commercial Management Team with Addition of Experienced New Hires

Apr 18, 2024, 8:30 AM EDT - 1 year ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare Initiatives

Mar 28, 2024, 4:05 PM EDT - 1 year ago

Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update

Mar 21, 2024, 9:00 AM EDT - 1 year ago

Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

Mar 20, 2024, 8:15 AM EDT - 1 year ago

Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility

Mar 6, 2024, 9:00 AM EST - 1 year ago

Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution

Feb 28, 2024, 9:00 AM EST - 1 year ago

Femasys' FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF

Feb 6, 2024, 8:30 AM EST - 1 year ago

Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer

Jan 26, 2024, 8:00 AM EST - 1 year ago

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women

Jan 23, 2024, 8:30 AM EST - 1 year ago

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology

Dec 15, 2023, 8:30 AM EST - 1 year ago

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine

Nov 30, 2023, 8:30 AM EST - 1 year ago

Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer

Nov 28, 2023, 8:40 AM EST - 1 year ago

Femasys: A Women's Health Medical Devices Company Ready To Turn The Corner

Nov 28, 2023, 8:30 AM EST - 1 year ago

Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch

Nov 15, 2023, 8:30 AM EST - 1 year ago

PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.

PMCB

Nov 15, 2023, 7:30 AM EST - 1 year ago

Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech

Nov 14, 2023, 7:00 AM EST - 1 year ago

Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2023 and Provides Corporate Update

Oct 26, 2023, 8:30 AM EDT - 1 year ago

Femasys Inc. EU MDR Final Audit Successfully Completed

Oct 11, 2023, 7:00 AM EDT - 1 year ago

Femasys Inc. Regains Compliance with Nasdaq Listing Requirements

Oct 4, 2023, 8:30 AM EDT - 1 year ago

Femasys Inc. to Showcase FemaSeed at the Annual Meeting of the American Society of Reproductive Medicine

Oct 3, 2023, 8:30 AM EDT - 1 year ago

Femasys Inc. MDSAP Surveillance Audit Successfully Completed

Oct 2, 2023, 6:00 AM EDT - 1 year ago

Femasys (FEMY) stock price is up 1,250% but there are 2 key risks

Sep 27, 2023, 8:00 AM EDT - 1 year ago

Femasys Inc. Expands FemBloc Pivotal Trial Enrollment Securing First Academic Site to Participate

Sep 26, 2023, 8:05 PM EDT - 1 year ago

FEMY stock price has surged: Is Femaysis still a good buy?

Sep 25, 2023, 5:25 PM EDT - 1 year ago

Femasys Inc. Receives U.S. FDA Clearance to Market FemaSeed, an Innovative Infertility Treatment Solution